Gossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed as Buy by Chardan Capital

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a report issued on Monday, Benzinga reports.

A number of other brokerages have also recently commented on GOSS. Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Tuesday, July 28th. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Finally, Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $256.00.

Gossamer Bio Stock Down 4.9%

Gossamer Bio stock traded down $0.47 during trading hours on Monday, reaching $9.13. 213,068 shares of the company’s stock were exchanged, compared to its average volume of 240,458. The firm has a market capitalization of $55.79 million, a PE ratio of -0.16 and a beta of 2.21. Gossamer Bio has a twelve month low of $8.29 and a twelve month high of $309.60. The firm’s 50 day simple moving average is $11.48 and its 200 day simple moving average is $16.16.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds have recently made changes to their positions in the stock. Corient Private Wealth LP boosted its position in shares of Gossamer Bio by 41.3% during the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after acquiring an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC boosted its stake in Gossamer Bio by 1,289.4% in the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after buying an additional 1,469,175 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Gossamer Bio during the second quarter worth about $65,000. Hhlr Advisors LTD. acquired a new stake in Gossamer Bio during the 2nd quarter valued at approximately $819,000. Finally, ARCH Venture Management LLC bought a new position in Gossamer Bio during the 2nd quarter worth approximately $1,326,004. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.